In a landmark move, President Donald Trump signed an executive order to reclassify marijuana from a Schedule I to a Schedule III drug, marking a significant shift in U.S. drug policy in December 2025.
This reclassification acknowledges the medical potential of cannabis, allowing for increased access to research and therapeutic uses while keeping it illegal at the federal level for recreational purposes.
The order has sparked a wave of reactions, from praise for initiating cannabis reform to strong opposition from Republican lawmakers who warn of public safety risks and claim Trump misrepresented GOP support.
Financially, the move could transform the marijuana industry, influencing stock markets and lending practices by easing federal restrictions on cannabis businesses.
While some medical experts support the change as a timely opportunity for patient care, concerns remain about the broader implications, including potential escalation in drug culture tied to cannabis use.
As debates swirl around the balance of state versus federal laws on marijuana, the executive order has ignited a renewed national conversation about the future of cannabis in America.
Top Keywords
Donald Trump/Ted Budd/White House/U.S. Attorney General/DEA/
96
